Roche announces giredestrant data as Roche Holding stock costs EUR 372.58
Published on 10/04/2026 at 17:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 1, 2026, Roche announced detailed giredestrant results from the phase III evERA Breast Cancer study, published in The New England Journal of Medicine, according to the company’s release. Roche Holding stock was EUR 372.58 in weekend trading at Lang & Schwarz at 5:33 p.m. CEST on October 4, 2026, unchanged from the EUR 372.58 close at Lang & Schwarz on October 2, 2026.
Weekend trading
The Lang & Schwarz price was EUR 372.58 at 5:33 p.m. CEST on October 4, 2026. The bid was EUR 371.95 and the ask was EUR 373.20. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Roche Holding stock.
Giredestrant study
Roche said giredestrant plus everolimus reduced the risk of disease progression or death by 44 percent in the intent-to-treat population and by 62 percent in the ESR1-mutated population versus standard endocrine therapy plus everolimus. In the ESR1-mutated population, median progression-free survival was 10.0 months with the combination and 5.5 months in the comparator arm, the company reported in its release.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026. Roche’s release said the US Food and Drug Administration set a December 18, 2026, goal date for giredestrant in advanced breast cancer and a November 30, 2026, goal date for early-stage breast cancer.
